人血清甲状腺激素检测现状评估——游离甲状腺素与促甲状腺素实验室间比对研究结果
美国CDC临床标准化项目对21种游离甲状腺素(fT4)检测和17种促甲状腺素(TSH)检测进行实验室间比对,检测41份盲法个体供者血清及3份混合血清。fT4免疫分析对参考测量程序呈负中位偏倚(-20.3%),仅21/40份样本被所有fT4检测一致分类;经线性回归再校准后一致分类升至33/40。结论强调fT4检测标准化对提高准确性和可比性的必要性。
要点
- fT4免疫分析对CDC参考测量程序呈负中位偏倚(-20.3%),实验室自建检测偏倚较小(-4.5%)。
- 再校准前仅21/40份个体供者血清被所有fT4检测一致分类,提示检测间一致性差。
- 再校准后一致分类升至33/40份,fT4免疫分析和自建检测的中位偏倚分别降至-0.2%和-0.3%。
核心结论
- fT4检测间比对强调需要测量标准化以提高准确性和可比性。
- 本研究及既往研究表明可通过标准化制定共同的fT4参考区间,使循证临床指南普遍用于患者诊疗。
- 再校准可有效解决fT4检测的高变异性,确保一致的诊断分类。
研究设计与样本
- 美国CDC临床标准化项目开展fT4免疫分析和实验室自建检测的实验室间比对,同时评估TSH免疫分析。
- 检测41份盲法个体供者血清(含1份孕妇样本,仅用于fT4分析)和3份混合血清,fT4为11.3-32.1 pmol/L(0.881-2.49 ng/dL)、TSH为0.337-21.6 mIU/L,双份检测2天。
- 采用Passing-Bablok回归分析比较检测与CDC fT4参考测量程序或TSH全实验室均值的一致性,并评估线性回归再校准的影响。
- 评估再校准前后按检测特异性参考区间进行样本分类的实验室间一致性。
主要发现
- 共21种fT4检测和17种TSH检测参与。
- 再校准前TSH检测对全实验室均值的中位偏倚为-1.2%(CI -1.8%至-0.4%),TSH检测间分类一致性良好。
- 再校准前所有fT4检测对参考测量程序均呈负中位偏倚,免疫分析偏倚(中位-20.3%,CI -21.5%至-19.4%)高于实验室自建检测(中位-4.5%,CI -6.1%至-3.2%)。
- 再校准前40份个体供者血清中仅21份被所有fT4检测一致分类,提示检测间一致性差。
- 再校准后40份个体供者血清中33份被所有受检免疫分析和自建检测正确分类;fT4免疫分析中位偏倚为-0.2%(CI -1.2%至0.6%),自建检测为-0.3%(CI -2.5%至1.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Performance of thyroid function assays can vary significantly. To address this issue, the Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs conducted an interlaboratory comparison of free thyroxine (fT4) immunoassays (IAs) and laboratory-developed tests (LDTs). This assessment aimed to determine the current performance characteristics of these assays as a first step toward measurement standardization. Thyrotropin (TSH) IAs were also evaluated. Methods: Assays measured 41 blinded individual-donor sera, including a sample from a pregnant woman (for fT4 analysis only) and three serum pools, with 11.3-32.1 pmol/L (0.881-2.49 ng/dL) fT4 and 0.337-21.6 mIU/L TSH in duplicate over 2 days. Passing-Bablok regression analysis performed pre-recalibration compared assays performance to the CDC fT4 reference measurement procedure (RMP) or TSH all-lab mean (ALM). Additionally, the impact of linear regression-based recalibration of assays to the CDC fT4 RMP or TSH ALM was estimated. Inter-assay agreement of sample classification according to the assay-specific reference interval (RI) was assessed pre- and post-recalibration. Results: A total of 21 fT4 and 17 TSH assays participated. Pre-recalibration, median biases of TSH measurements to the ALM were -1.2% [confidence interval or CI -1.8% to -0.4%], and good classification agreement among TSH assays was observed. fT4 assays all showed a negative median bias to the RMP, with higher bias among IAs (median: -20.3%, CI [-21.5% to -19.4%]) than LDTs (median: -4.5%, [CI -6.1% to -3.2%]). Of the individual-donor sera, only 21 out of 40 samples were classified uniformly by all fT4 assays, indicating poor inter-assay agreement. Post-recalibration, agreement improved to 33 out of 40 individual-donor sera correctly classified by all tested IAs and LDTs. Similar improvement in post-recalibration median percent bias was observed for fT4 IAs (median: -0.2, [CI -1.2% to 0.6%]) and LDTs (median: -0.3%, [CI -2.5% to 1.4%]). Conclusions: The comparison among fT4 assays emphasizes the need for measurement standardization to improve accuracy and comparability. This and previous studies demonstrate the possibility to develop common fT4 RIs via standardization, enabling the use of evidence-based clinical guidelines universally in patient care. Recalibration can effectively address high variability in fT4 assays, ensuring consistent diagnostic classification.
引用
- Ribera A, Sugahara O, Buchannan T, et al. Evaluation of the Current State of Thyroid Hormone Testing in Human Serum-Results of the Free Thyroxine and Thyrotropin Interlaboratory Comparison Study. Thyroid. 2025. PMID: 40333029. doi:10.1089/thy.2024.0728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。